QUOTE AND NEWS
New York Times  Nov 25  Comment 
The move by the European Commission puts pressure on the company’s Danish rival, Novo Nordisk, the market leader in its category.
Market Intelligence Center  Nov 18  Comment 
MarketIntelligenceCenter.com's patented algorithms have selected a trade on Eli Lilly and Co (LLY) that returns 7.37% in 60 days for an annualized return rate of 45%. This diagonal spread pairs a short position in the Jan. '15 $67.50 call, with a...
Forbes  Nov 17  Comment 
Shareholders of Eli Lilly & Co. (NYSE: LLY) looking to boost their income beyond the stock's 2.9% annualized dividend yield can sell the January 2017 covered call at the $75 strike and collect the premium based on the $3.85 bid, which annualizes...
Forbes  Nov 13  Comment 
At Holdings Channel, we have reviewed the latest batch of the 32 most recent 13F filings for the 09/30/2014 reporting period, and noticed that Eli Lilly & Co. (NYSE: LLY) was held by 15 of these funds. When hedge fund managers appear to be...
Forbes  Nov 10  Comment 
In afternoon trading on Monday, Healthcare stocks are the best performing sector, up 0.8%. Within that group, AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) are two large stocks leading the way, showing a gain of 3.5% and 2.6%, respectively. Among...
newratings.com  Nov 10  Comment 
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) said Monday that Trulicity, a once-weekly, glucagon-like peptide-1 receptor agonist injectable prescription medicine indicated as an adjunct to diet and exercise to improve glycemic control in...
Jutia Group  Nov 10  Comment 
[PR Newswire] - INDIANAPOLIS, Nov. 10, 2014 /PRNewswire/ -- The newest GLP-1 receptor agonist treatment option to help improve glycemic control type 2 diabetes in adults is now available in U.S. pharmacies. Eli Lilly ... Read more on this. Eli...
newratings.com  Nov 5  Comment 
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co (LLY) said Wednesday the U.S. Food and Drug Administration has approved Cyramza (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic...
StreetInsider.com  Nov 5  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Lilly+%26+Co.+%28LLY%29+Reports+FDA+Approval+of+CYRAMZA+Combo+as+GEJ+Adenocarcinoma+Treatment/9979262.html for the full story.
Jutia Group  Nov 5  Comment 
[PR Newswire] - INDIANAPOLIS, Nov. 5, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA ® (ramucirumab) in combination with paclitaxel ... Read more on...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki